TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AIM ImmunoTech ( (AIM) ) has issued an announcement.
AIM ImmunoTech has filed an amended and restated Certificate of Incorporation, which supersedes all previous versions. This update may have implications for the company’s governance and operational structure.
The most recent analyst rating on (AIM) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Neutral.
AIM ImmunoTech’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, negative profitability, and weak balance sheet. Technical analysis and valuation also contribute to a low score, with negative momentum indicators and unattractive valuation metrics. The absence of earnings call data and corporate events leaves these areas unaddressed.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
Average Trading Volume: 111,127
Technical Sentiment Signal: Sell
Current Market Cap: $6.88M
For an in-depth examination of AIM stock, go to TipRanks’ Overview page.